A case of urothelial carcinoma with successful continuation of enfortumab vedotin without dose reduction despite grade 3 diffuse erythema with fever

Eur J Dermatol. 2024 Apr 1;34(2):214-216. doi: 10.1684/ejd.2024.4655.

Authors

Shuta Yoshitani¹, Kazuma Kaneda¹, Mio Nishida¹, Kazumasa Komura², Shinichi Moriwaki¹, Atsushi Fukunaga¹

Affiliations

¹ Department of Dermatology, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-0801, Japan.
² Department of Urology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-cho, Takatsuki, Osaka, 569-0801, Japan.

PMID: 38907560
DOI: 10.1684/ejd.2024.4655

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / pathology
Erythema* / drug therapy
Erythema* / pathology
Fever* / etiology
Humans
Male
Urinary Bladder Neoplasms / drug therapy
Urinary Bladder Neoplasms / pathology